Enzalutamide combining with ADT as neoadjuvant therapy for prostate cancer: a case report
10.3760/cma.j.cn112330-20210908-00017
- VernacularTitle:恩扎卢胺联合ADT用于前列腺癌新辅助治疗一例报告
- Author:
Gaoyang YANG
1
;
Yunxin ZHANG
;
Zhenxing ZHAI
;
Yuhan WANG
;
Juan WANG
;
Zhiping WANG
Author Information
1. 兰州大学第二医院泌尿外科 甘肃省泌尿系疾病研究重点实验室，兰州 730000
- Keywords:
Prostate cancer;
Hormone sensitive;
Enzalutamide;
Treatment
- From:
Chinese Journal of Urology
2021;42(Z2):57-60
- CountryChina
- Language:Chinese
-
Abstract:
Traditional endocrine drugs, such as bicalutamide, are the first choice for neoadjuvant therapy of prostate cancer. There are few reports on the use of new endocrine drugs in neoadjuvant therapy in China. The patient, male, 63 years old. He was admitted to the hospital for the finding of prostate space occupying. Blood PSA 53.50 ng / ml. Prostate MRI suggested that the prostate lesion broke through the left capsule, the left seminal vesicle gland was invaded, and the bladder wall was invaded. Bone scan suggested that: the left 8th posterior costal branch radioactivity was limited and increased. Prostate adenocarcinoma was diagnosed by puncture, Gleason score 4 + 4 = 8 points, and stage T 4bN 1M 1. The patient was treated with goserelin combined with enzalutamide for 3 months, and PSMA-PET CT: prostate size was normal, no significant 68Ga PSMA uptake was increased, no abnormally high Ga PSMA uptake in bones. The patient was treated with enzalutamide combined with ADT as neoadjuvant endocrine therapy, winning surgical conditions for the patient to undergo surgical resection.
